Published in J Neural Transm (Vienna) on July 14, 2011
Objective biomarkers of balance and gait for Parkinson's disease using body-worn sensors. Mov Disord (2013) 1.15
Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One (2012) 1.06
Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis (2012) 1.00
Oxidative stress in genetic mouse models of Parkinson's disease. Oxid Med Cell Longev (2012) 0.98
Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. Int J Alzheimers Dis (2012) 0.89
Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) (2015) 0.85
Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease. Sci Rep (2012) 0.81
Iron and Oxidative Stress in Parkinson's Disease: An Observational Study of Injury Biomarkers. PLoS One (2016) 0.79
Specific changes of serum proteins in Parkinson's disease patients. PLoS One (2014) 0.78
Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm (Vienna) (2015) 0.77
Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors. PLoS One (2016) 0.76
Neurophysiological biomarkers for Lewy body dementias. Clin Neurophysiol (2015) 0.76
Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease. Oncotarget (2016) 0.76
Differential proteomics analysis of mononuclear cells in cerebrospinal fluid of Parkinson's disease. Int J Clin Exp Pathol (2015) 0.75
Metabolomics and the search for biomarkers in Parkinson's disease. Mov Disord (2013) 0.75
Icariin reduces α-synuclein over-expression by promoting α-synuclein degradation. Age (Dordr) (2015) 0.75
Laboratory assessments in the course of Parkinson's disease: a clinician's perspective. J Neural Transm (Vienna) (2015) 0.75
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging (1998) 5.05
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol (1998) 4.48
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature (1988) 3.12
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol (2005) 2.94
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol (2005) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Changes in network activity with the progression of Parkinson's disease. Brain (2007) 2.46
Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology (2004) 2.35
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Pathophysiology of bradykinesia in Parkinson's disease. Brain (2001) 2.24
Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1999) 2.23
Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol (2009) 2.21
Can an accelerometer enhance the utility of the Timed Up & Go Test when evaluating patients with Parkinson's disease? Med Eng Phys (2009) 2.16
Measurement of stand-sit and sit-stand transitions using a miniature gyroscope and its application in fall risk evaluation in the elderly. IEEE Trans Biomed Eng (2002) 2.14
Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol (2010) 2.12
Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain (2008) 2.10
The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease. J Neurol Neurosurg Psychiatry (2009) 2.07
Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology (2001) 2.06
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain (2010) 2.01
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology (2002) 1.91
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med (2009) 1.78
Bilateral coordination of gait and Parkinson's disease: the effects of dual tasking. J Neurol Neurosurg Psychiatry (2009) 1.70
Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol (1991) 1.65
Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology (2008) 1.59
Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol (2009) 1.58
A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain (2005) 1.57
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol (2002) 1.55
Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm (1976) 1.54
A new measure for quantifying the bilateral coordination of human gait: effects of aging and Parkinson's disease. Exp Brain Res (2007) 1.50
Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord (2006) 1.49
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun (2006) 1.45
Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain (2000) 1.45
The rate of cognitive decline in Parkinson disease. Arch Neurol (2004) 1.44
Properties of the 'timed up and go' test: more than meets the eye. Gerontology (2010) 1.40
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis (2008) 1.39
(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry (1999) 1.38
Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain (1993) 1.38
Postural abnormalities to multidirectional stance perturbations in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 1.36
Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord (2008) 1.33
Anticipatory postural adjustments prior to step initiation are hypometric in untreated Parkinson's disease: an accelerometer-based approach. Eur J Neurol (2009) 1.32
Locomotor function in the early stage of Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng (2007) 1.30
Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J Neurochem (2009) 1.27
Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology (2005) 1.26
Quantification of trunk rotations during turning and walking in Parkinson's disease. Clin Neurophysiol (2007) 1.22
Trunk sway measurements during stance and gait tasks in Parkinson's disease. Gait Posture (2005) 1.22
Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord (2003) 1.19
Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One (2009) 1.19
Biomarkers and Parkinson's disease. Brain (2004) 1.17
Review: Familial Parkinson's disease--genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol (2008) 1.17
Uric acid in Parkinson's disease. Mov Disord (2008) 1.17
Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett (2007) 1.15
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord (2001) 1.13
Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl (1995) 1.09
Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord (2007) 1.07
Molecular basis of Parkinson's disease. Neuroreport (2009) 1.06
Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci (2010) 1.06
Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to "PARK" genes and beyond. Mov Disord (2009) 1.05
Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann Neurol (2008) 1.03
Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci (2009) 1.03
Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis (2006) 1.03
Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med (2010) 1.01
Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol (2010) 0.99
Head and trunk rotation during walking turns in Parkinson's disease. Mov Disord (2008) 0.98
Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol (2007) 0.98
Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm (Vienna) (2003) 0.97
Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol (2009) 0.96
Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol Sci (2002) 0.94
Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun (2006) 0.93
Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology (2005) 0.93
Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology (2005) 0.93
Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord (2010) 0.92
Insomnia in Parkinson's disease: frequency and progression over time. J Neurol Neurosurg Psychiatry (2006) 0.92
Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm (Vienna) (2010) 0.92
Comparison of a timed motor test battery to the Unified Parkinson's Disease Rating Scale-III in Parkinson's disease. Mov Disord (2008) 0.90
Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Mov Disord (2009) 0.90
Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J Neuropathol Exp Neurol (2011) 0.89
Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci (2008) 0.88
Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. Mov Disord (2009) 0.88
Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol (1995) 0.88
Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (2010) 0.87
Alzheimer's disease and total plasma aminothiols. Biol Psychiatry (2003) 0.87
Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol (2009) 0.86
Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand (2008) 0.86
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Mild cognitive impairment. Lancet (2006) 10.21
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med (2003) 6.79
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci (2007) 5.68
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. Neuroimage (2005) 4.83
Burnout: a fashionable diagnosis. Dtsch Arztebl Int (2011) 4.64
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol (2006) 2.62
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol (2008) 2.42
Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol (2005) 2.40
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology (2007) 2.39
Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex (2004) 2.36
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int (2013) 2.22
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell (2013) 2.22
Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med (2002) 2.12
Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiol Aging (2006) 2.09
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J (2007) 1.94
Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry (2007) 1.93
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet (2010) 1.86
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain (2005) 1.85
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res (2012) 1.74
Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry (2012) 1.70
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology (2007) 1.61
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet (2009) 1.59
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol (2009) 1.58
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke (2002) 1.57
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells (2009) 1.57
Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. Neuroimage (2009) 1.55
Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry (2009) 1.54
A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat (2013) 1.53
Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage (2006) 1.52
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology (2012) 1.51
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem (2005) 1.51
Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry (2010) 1.49
Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med (2007) 1.48
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
SNCA: major genetic modifier of age at onset of Parkinson's disease. Mov Disord (2013) 1.48
BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res (2006) 1.46
Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol (2011) 1.45
Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain (2004) 1.45
Progression of corpus callosum atrophy in Alzheimer disease. Arch Neurol (2002) 1.44
Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry (2011) 1.43
The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci (2004) 1.42
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Transcranial sonography as a diagnostic tool for Parkinson's disease: a pilot study in the city of Rio de Janeiro, Brazil. Arq Neuropsiquiatr (2011) 1.40
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis (2008) 1.39
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 1.38
Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem (2007) 1.37
Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol (2007) 1.37
Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord (2007) 1.35
Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. Neurobiol Aging (2010) 1.35
Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol (2007) 1.34
Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J Neurosci (2004) 1.33
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.29
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
White matter microstructure underlying default mode network connectivity in the human brain. Neuroimage (2009) 1.29
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol (2006) 1.29
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem (2007) 1.28
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry (2010) 1.27
Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. J Alzheimers Dis (2010) 1.27
Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years. Brain (2006) 1.27